R&D Locations

Pfizer Global Research & Development has four major locations across the United States and England. While Pfizer colleagues at each center employ unique technologies to focus on site-specific functions and therapeutic areas, together they comprise an integrated global network of discovery and development. Global databases and streamlined distribution work to create a synergy of ideas, tools, and expertise that drive a robust pipeline and help Pfizer researchers and scientists create some of the most promising new medicines to help improve the health and wellness of people around the world.

Pfizer Research at Groton & New London, Connecticut

Site Statistics:

• 160–acre site with 2.7 million–square–feet of state–of–the–art facility space at Groton—the largest pharmaceutical research facility of its kind in the world
• 780,000–square–foot facility located on a 29–acre peninsula at New London
• More than 4,000 highly skilled research scientists, technicians, clinicians, and other professionals employed at Groton
• 2,000 members of the Pfizer global development team employed at New London

Functions: Discovery, Drug Metabolism, Pharmaceutical Sciences, Development, Animal Health, and Drug Effectiveness and Safety Evaluation

Therapeutic Areas: Inflammation Development, Infectious Diseases (Antibacterials), Cardiovascular/Metabolic Diseases, Neurosciences, Dermatology

Key Technologies: Molecular Profiling, GeMM (Genetically Modified Models), Liquid Materials Management, Reagent Antibody, Discovery High Throughput Screening, ADME (absorption, distribution, metabolism, excretion and toxicity) Screening, Biocatalysis, Microbiology, Spray Dried Dispersion, Parental Form, DART, Safety Pharmacology, Whole Body, Biobank

Read more about Pfizer Groton & New London—the center of Pfizer Global Research & Development.

Visit Pfizer Groton/New London

Pfizer Research at Sandwich, England

Site Statistics

• 390–acre site with 2.2 million–square–feet of facility space–the largest pharmaceutical research center outside the U.S. affiliated with a U.S. company
• More than 2,700 scientists and 900 manufacturing staff

Functions: Discovery, Drug Metabolism, Pharmaceutical Sciences, Development, Animal Health and Drug Safety Evaluation

Therapeutic Areas: Allergy & Respiratory, Infectious Diseases (Antivirals), Genitourinary, Gastrointestinal & Hepatology, Pain

Key Technologies: Discovery High Throughout Screening, Inhalation, Device Development, ADME (absorption, distribution, metabolism, excretion and toxicity) Screening, Safety Pharmacology

Read more about the global role of Pfizer Sandwich.

Visit Pfizer Sandwich

Pfizer Research at La Jolla, California

Site Statistics:

• 33.5–acre campus with more than 1 million–square–feet of state–of–the–art facility space
• 1,000 scientists and support staff

Functions: Discovery, Drug Metabolism, Pharmaceutical Sciences, Development and Drug Safety Evaluation

Therapeutic Areas: Oncology and Ophthalmology

Key Technologies: Structural and Computational Biology, Molecular Design, High Throughput Chemistry, and Pharmacology

Read more about the exciting research taking place at Pfizer La Jolla.

Visit Pfizer La Jolla

Pfizer Research at St. Louis, Missouri

Site Statistics:

• Four campuses covering a total area of 200 acres and containing 1.2 million square feet of lab space
• Construction on a new $200 million, 330,000–square–foot research building scheduled to be completed in late 2008 to allow Pfizer to consolidate research in St. Louis to a single campus
• 1,200 colleagues

Functions: Discovery and Biologics

Therapeutic Areas: Inflammation

Key Technologies:

Read more about Pfizer St. Louis—the global center of emphasis for Biologics.

Visit Pfizer St. Louis

Pfizer Research at Rinat, South San Francisco, California

In 2006, Pfizer expanded neuroscience research and acquired Rinat, a biotechnology company in South San Francisco. It is now a part of Pfizer Global Research & Development and is an integral part of the company's biotherapeutic discovery efforts.

Pfizer Research at Cambridge, Massachusetts

Founded in 1999, the Research Technology Center (RTC) is a small, vibrant, and fully functional PGRD site, located in the heart of Boston's academic, biotechnology, and medical hub. The mission of the RTC is to apply cutting edge technologies to address specific challenges that prevent patients from receiving the innovative medicines they need. By setting up this one-of-a-kind operation, we have created an entrepreneurial environment that offers our scientists freedom to take risks and infuse our research with innovation.

• Cambridge, Massachusetts – Pfizer Research Technology Center (RTC)

---

As announced on January 22, 2007, Pfizer intends to exit its R&D facilities at Amboise, France, Ann Arbor, Michigan, Kalamazoo, Michigan, and Nagoya, Japan with much of their work relocated to other sites. This will take place during 2007 and 2008. These sites have played important roles and made significant contributions to the research and development of new medicines:

Amboise, France

Amboise, France, was established in 1970 to determine the preclinical safety of compounds destined for the European market. Today, the Amboise site provides toxicology and exploratory study support. Projects will be absorbed within a reorganization of Pfizer's Drug Safety R&D organization and transferred to other locations.

Ann Arbor, Michigan

The Ann Arbor site, which had been a Warner-Lambert/Parke-Davis facility prior to the company's merger with Pfizer, began operating in 1960, with 256,000 square feet of lab and office space.

The 90-acre expanded site is home to more than 2-million square feet of lab and office space. It includes a state-of-the-art building for product and technical development research, as well as a new fully integrated discovery facility.

Esperion, Ann Arbor, MI

In 2003, Pfizer acquired Esperion Therapeutics, Inc., a biopharmaceutical company formed in 1998 and focused on the discovery and development of high density lipoprotein (HDL)-targeted therapies for the treatment of cardiovascular disease. Esperion was a division within Pfizer Global Research and Development prior to Pfizer's decision to close its three Michigan R&D facilities. Projects previously managed by Esperion have been transferred to Groton, Connecticut.

Kalamazoo, MI

Pfizer's research labs in Kalamazoo date to the early years of the 20th Century, when the Upjohn Company started hiring scientists to ensure the quality of products and to develop new medicines. After Pfizer's acquisition of Pharmacia (formerly Pharmacia & Upjohn) in 2003, work at the Kalamazoo Laboratories was refocused on the disciplines of pharmaceutical sciences and drug safety R&D, and later, on drug safety R&D alone. That work will be transferred to other Pfizer research facilities.

Nagoya, Japan

The Nagoya site was established in 1972 at an existing Pfizer facility. R&D functions located at Nagoya are Discovery, Drug Metabolism, Pharmaceutical Sciences, Development, Animal Health and Drug Safety Evaluation. Therapeutic areas currently being researched at Nagoya are Pain, Gastrointestinal Disorders and Antivirals.

For more information, visit the Research & Development section.

• Go to Research & Development